BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dézsi L, Vécsei L. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 2014;10:409-24. [DOI: 10.1517/17425255.2014.878702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Poirier AA, Aubé B, Côté M, Morin N, Di Paolo T, Soulet D. Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments. Parkinsons Dis 2016;2016:6762528. [PMID: 28050310 DOI: 10.1155/2016/6762528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
2 Raja Naika H, Krishna V, Lingaraju K, Chandramohan V, Dammalli M, Navya P, Suresh D. Molecular docking and dynamic studies of bioactive compounds from Naravelia zeylanica (L.) DC against glycogen synthase kinase-3β protein. Journal of Taibah University for Science 2018;9:41-9. [DOI: 10.1016/j.jtusci.2014.04.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Majláth Z, Török N, Toldi J, Vécsei L. Promising therapeutic agents for the treatment of Parkinson’s disease. Expert Opinion on Biological Therapy 2016;16:787-99. [DOI: 10.1517/14712598.2016.1164687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016; 6(1): 1-19 [PMID: 27019793 DOI: 10.5662/wjm.v6.i1.1] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
5 Parambi DGT. Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Comb Chem High Throughput Screen 2020;23:847-61. [PMID: 32238135 DOI: 10.2174/1386207323666200402090557] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Dong J, Cui Y, Li S, Le W. Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. Curr Neuropharmacol 2016;14:339-55. [PMID: 26585523 DOI: 10.2174/1570159x14666151120123025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
7 Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. Expert Opin Drug Metab Toxicol 2016;12:433-48. [PMID: 26910127 DOI: 10.1517/17425255.2016.1158250] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
8 Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:465-81. [PMID: 26893541 DOI: 10.2147/DDDT.S79458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]